Core Viewpoint - The company, Yiqiao Shenzhou Technology Co., Ltd., reported strong financial performance for Q3 2025, with significant growth in both revenue and net profit, driven by domestic and international business expansion [3][4]. Group 1: Financial Performance - For the first three quarters of 2025, the company achieved a revenue of 186.99 million yuan, representing a year-on-year increase of 17.39% [3] - The net profit for the same period reached 110.18 million yuan, up by 10.94% year-on-year [3] - In Q3 alone, the net profit was 42.49 million yuan, showing a remarkable growth rate of 49.76% compared to the previous year [3] Group 2: Business Development - The company is experiencing stable growth in both domestic and international markets, with a focus on expanding its market share and brand recognition in China while enhancing its overseas presence [4] - The domestic market has shown strong demand, while the overseas market, although in its early stages, presents significant growth potential due to competitive product pricing [4] Group 3: Product Strategy - The company is implementing a dual-track strategy for cytokine products, balancing GMP and non-GMP offerings to cater to different customer needs [5] - The SCB business segment has shown steady revenue growth, with initial signs of successful integration and collaboration between the company's existing capabilities and the SCB products [6] - The company currently offers over 9,800 types of protein products, positioning itself as a global leader, with plans to enhance product quality and expand antibody offerings through innovation [7]

Financial Performance - In the first three quarters of 2025, the company's revenue reached 51,144.50 million yuan, a year-on-year increase of 10.00% [3] - In Q3 2025, the company achieved revenue of 18,698.98 million yuan, reflecting a year-on-year growth of 17.39% [3] - The net profit for the first three quarters was 11,017.95 million yuan, up 10.94% year-on-year; in Q3, net profit was 4,249.32 million yuan, showing a significant increase of 49.76% [3] Market Development - Domestic business has shown stable growth due to increased industry demand and market expansion, with a solid market share and brand recognition [4] - The overseas market, while still developing, presents significant growth potential due to competitive product pricing and planned marketing efforts to enhance brand awareness [4] Product Development - The company offers two categories of cytokine products: non-GMP for research purposes and GMP-certified for industrial use, with a balanced strategy to expand GMP product offerings [5] - The company has a leading position with over 9,800 types of protein products, focusing on quality upgrades to enhance customer satisfaction [6] - There is an ongoing effort to increase the number of antibody products through continuous R&D innovation [6] Collaboration and Synergy - The collaboration with SCB has resulted in steady revenue growth, with initial integration of product lines enhancing market coverage, particularly in North America [6]